SCHEMBL2508396

SCHEMBL2508396

C1=N[N]C2CCCCC2=C1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.31
NOS1 P29475 2/20 0.31
NOS2 P35228 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL447339 0.67 NOS1 (0.31) NOS1NOS2
SCHEMBL2505613 0.60 NOS1 (0.32) NOS1NOS2
SCHEMBL486034 0.59 ESR1 (0.36) KDM1A
SCHEMBL24307650 0.58 NOS2 (0.34) NOS1NOS2
SCHEMBL2505604 0.58 KDM1A (0.39) KDM1ANOS1NOS2
SCHEMBL2508260 0.57 NOS1 (0.30) NOS1NOS2
SCHEMBL2504437 0.57 NOS1 (0.30) NOS1NOS2
SCHEMBL2507828 0.57 KDM1A (0.31) KDM1A
SCHEMBL4774055 0.56 NOS1 (0.33) NOS1NOS2
SCHEMBL6470349 0.56 KDM1A (0.46) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYTOKINE PHARMASCIENCES, INC. (US) 2011-10-06 US claimed
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYTOKINE PHARMASCIENCES, INC. (US) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE DDX5, SAMHD1, EIF2AK2 KDM1A 4048/4885NOS1 3990/4885NOS2 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.